{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:04:42Z","timestamp":1779955482496,"version":"3.53.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jcf.2025.04.008","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T07:22:04Z","timestamp":1746429724000},"page":"916-919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends in Medicare versus Medicaid spending on CFTR modulator therapy \u2013 an economic evaluation"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5312-425X","authenticated-orcid":false,"given":"Wanjae","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Parkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6820-6211","authenticated-orcid":false,"given":"Christina S.","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-3531","authenticated-orcid":false,"given":"Stephen E.","family":"Congly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10290","key":"10.1016\/j.jcf.2025.04.008_bib0001","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2025.04.008_bib0002","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jcf.2025.04.008_bib0003","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcf.2024.08.002","article-title":"Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union","volume":"24","author":"Costa","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"10212","key":"10.1016\/j.jcf.2025.04.008_bib0004","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2025.04.008_bib0005","unstructured":"Centers for Medicare and MedicaidServices. Medicare part D spending by drug [Internet]. 2024. Available from: https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug\/medicare-part-d-spending-by-drug."},{"key":"10.1016\/j.jcf.2025.04.008_bib0006","unstructured":"Centers for Medicare and Medicaid Services. Medicaid spending by drug [Internet]. 2024. Available from: https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug\/medicaid-spending-by-drug."},{"key":"10.1016\/j.jcf.2025.04.008_bib0007","unstructured":"Cystic Fibrosis Foundation. 2023 Cystic Fibrosis Foundation Patient Registry Annual Data Report [Internet]. Available from: https:\/\/www.cff.org\/medical-professionals\/patient-registry."},{"key":"10.1016\/j.jcf.2025.04.008_bib0008","unstructured":"Alioth Finance. 2025. \u201cInflation calculator.\u201d U.S. Official Inflation data."},{"key":"10.1016\/j.jcf.2025.04.008_bib0009","unstructured":"U.S. Centers for Medicare and Medicaid Services. Medicaid [Internet]. 2024. Available from: https:\/\/www.medicare.gov\/basics\/costs\/help\/medicaid."},{"key":"10.1016\/j.jcf.2025.04.008_bib0010","unstructured":"U.S. Centers for Medicare and Medicaid Services. 2024. Medicaid Drug Rebate Program (MDRP) [Internet]. Available from: https:\/\/www.medicaid.gov\/medicaid\/prescription-drugs\/medicaid-drug-rebate-program\/index.html."},{"issue":"4","key":"10.1016\/j.jcf.2025.04.008_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2024.101509","article-title":"Spending on nucleos(t)ide analogues for hepatitis B in medicaid beneficiaries: 2012-2021","volume":"29","author":"Congly","year":"2024","journal-title":"Ann Hepatol"},{"issue":"2","key":"10.1016\/j.jcf.2025.04.008_bib0012","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.gastro.2023.08.012","article-title":"Medicare Part D spending for Hepatitis B Virus drugs: completing the picture and extending the dataset","volume":"166","author":"Congly","year":"2024","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jcf.2025.04.008_bib0013","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.008_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211037459","article-title":"Impact of COVID-19 on social determinants of health for adults with cystic fibrosis","volume":"15","author":"Albon","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jcf.2025.04.008_bib0015","unstructured":"U.S. Centers for Medicare and Medicaid Services. Prescription drug law [Internet]. 2024. Available from: https:\/\/www.cms.gov\/inflation-reduction-act-and-medicare\/medicare-drug-price-negotiation."}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325014638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325014638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:34:57Z","timestamp":1779953697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325014638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1569199325014638"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.04.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in Medicare versus Medicaid spending on CFTR modulator therapy \u2013 an economic evaluation","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}